Home » Topics » BioWorld Science

BioWorld Science
RSS

Crinetics Pharmaceuticals describes new melanocortin MC2 receptor antagonists

Dec. 20, 2019

Scientists report insights into the mechanics, literally, of IPF

Dec. 20, 2019

New plasma biomarkers found for amyotrophic lateral sclerosis

Dec. 20, 2019

Spravato nasal spray approved in Europe

Dec. 20, 2019

NexImmune receives IND clearance for phase I/II study of NEXI-002 in multiple myeloma

Dec. 20, 2019

Embera NeuroTherapeutics receives funding to advance EMB-001 into phase II studies

Dec. 20, 2019

First patient enrolled in phase III GUARD study of ADX-2191 for prevention of PVR

Dec. 20, 2019

Results from the first patient cohort of INSIGHT-004 phase I study

Dec. 20, 2019

Topline data presented from E.U. phase III study of Wynzora Cream for psoriasis vulgaris

Dec. 20, 2019

Gamida Cell presents phase I data for cellular therapy using GDA-201

Dec. 20, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...